

Company Overview

Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) is a leader in precision medicine with immuno-targeted products designed to help identify the sites and pathways of undetected disease and enable better diagnostic accuracy, clinical decision-making, targeted treatment and, ultimately, patient care. Applying our Manocept™ technology, Navidea seeks to develop next-generation targeted diagnostics and therapies for cancer, autoimmune conditions, and other inflammatory diseases. The company, founded in 1983, maintains headquarters in Dublin, Ohio.

Navidea Biopharmaceuticals, Inc. Announces Extension of Authority to Implement a Reverse Stock Split

May 21 2025, 2:52 PM EDT

Navidea Biopharmaceuticals Announces the Extension of Plan Designed to Protect NOLs and Other Tax Assets

Mar 31 2025, 6:08 PM EDT

Navidea Biopharmaceuticals, Inc. Announces Results of Exploratory Analysis Completed on July 2, 2024

Jul 3 2024, 4:30 PM EDT

Stock Overview

Symbol

NAVB

Exchange

NYSE American

Market Cap

50.04k

Last Price

\$0.0005

52-Week

\$0.0001 - \$0.13

Investor Relations

T: (614) 822-2322

investorrelations@navidea.com

08/21/2025 01:30 PM EDT

Management Team

Michael Blue, M.D., FACEP

Chief Medical Officer

Craig A. Dais, CPA

Chief Financial Officer

Navidea Biopharmaceuticals, Inc.

4100 Horizons Drive

Suite 205

Columbus, OH 43220

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and it's quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.